공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

단순 헤르페스 바이러스(HSV) 치료 시장 : 성장, 동향, 예측(2020-2025년)

Herpes Simplex Virus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 05월 상품 코드 927810
페이지 정보 영문
가격
US $ 4,250 ₩ 5,044,000 PDF (Single User License)
US $ 4,750 ₩ 5,637,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,121,000 PDF (Site License)
US $ 7,500 ₩ 8,901,000 PDF (Corporate License)


단순 헤르페스 바이러스(HSV) 치료 시장 : 성장, 동향, 예측(2020-2025년) Herpes Simplex Virus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

단순 헤르페스 바이러스 치료 시장은 단순 헤르페스 바이러스 만연에 의해 예측기간 동안 5.9%의 연평균 복합 성장률(CAGR을 나타낼 것으로 예측되고 있습니다. 단순 헤르페스 바이러스는 HSV-1과 HSV-2의 두 종류가 있습니다. 세계보건기구에 따르면 2017년에는 전세계 50세 미만인 약 37억 명이 HSV-1으로 진단을 받았고, 또한 HSV-2는 11-49세에서 4억 1,700만명이 발생했습니다. 따라서 단순 헤르페스 바이러스의 유병률의 증가는 시장 성장을 뒷받침 할 것으로 예상됩니다.

세계의 단순 헤르페스 바이러스(HSV: Herpes Simplex Virus) 치료 시장을 조사했으며, 시장 개요, 약제 별·투여경로별·지역별 시장 규모 추이 및 예측, 시장 동향, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, 경쟁 상황, 주요 기업 프로파일 등의 종합적인 정보를 전해드립니다.

목차

제1장 서론

  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 성기 헤르페스의 확산
    • 증가하는 연구개발 활동
  • 시장 성장 억제요인
    • 제품 리콜
  • Porter's Five Forces 분석
    • 신규 진출기업의 위협
    • 구매자의 교섭력
    • 공급업체의 협상력
    • 대체품의 위협
    • 경쟁

제5장 시장 세분화

  • 약제별
    • Acyclovir
    • Valacyclovir
    • Famciclovir
    • 기타
  • 투여 경로별
    • 구경
    • 주입
    • 국소
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Teva Pharmaceuticals Inc.
    • Apotex Inc.
    • Mylan Pharmaceuticals Inc.
    • Epi Health LLC
    • Zydus Pharmaceuticals
    • GlaxoSmithKline LLC
    • Carlsbad Tech
    • Avet Pharmaceuticals Inc.
    • Glenmark Pharmaceuticals
    • Fresenius Kabi

제7장 시장 기회 및 향후 동향

LSH 20.05.27

The Herpes Simplex Virus Treatment Market is expected to register a CAGR of 5.9% during the forecast period owing to growing prevalence of simplex herpes virus. Herpes Simplex Virus is of two types, HSV-1 and HSV-2. According to the World Health Organization, in 2017, around 3.7 billion people globally, were diagnosed with HSV-1 aged under fifty. Moreover, HSV-2 occurred in 417 million people worldwide aged between 11 and 49. Hence, such higher prevalence of herpes simplex virus is expected to boost the market growth.

Key Market Trends

Acyclovir Segment is Expected to Hold a Significant Market Share in the Herpes Simplex Virus Treatment Market

  • Acyclovir is a anti-viral therapy considered as the majorly used treatment in case of herpes, used against oral herpes and HSV encephalitis. It is purine nucleoside analog that enters into viral DNA to restrict it's replication process by converting into acyclovir triphosphate. According to the study published in 2019, by Frontiers in Microbiology acyclovir when given in combination with omeprazole increased the anti-viral effects in HSV-1 and HSV-2 infection.
  • Also, growing burden of HSV encephalitis is expected to boost the market in this particular segment. According to National Organizations for Rare Disorders, the incidence of acute encephalitis in the United States is around 2,000 cases per year and it constitutes for atleast 10% of total cases of encephalitis occurring in the United States.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to be dominant in genital herpes market owing to growing prevalence of infections of herpes simplex virus. According to American Sexual Health Association, approximately fifty percent of population in the United States suffers from oral herpes which is caused by HSV-1. Furthermore, around one in eight people is likely to suffer from HSV-2 infection. Moreover, according to the National Institutes of Health, by the age of 50 around 90% of people in the United States are exposed to this virus. Hence, this emerges the need for treatment of herpes and thereby expected to drive the herpes simplex virus treatment market.

Competitive Landscape

Some of the companies which are currently dominating the market are Teva Pharmaceuticals Inc., Apotex Inc., Mylan Pharmaceuticals Inc., Epi Health LLC, Zydus Pharmaceuticals, GlaxoSmithKline LLC, Carlsbad Tech, Avet Pharmaceuticals Inc., Glenmark Pharmaceuticals Inc. and Fresenius Kabi

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden Of Herpes Simplex Virus Infections Such As Genital Herpes
    • 4.2.2 Increasing Research and Development Activities
  • 4.3 Market Restraints
    • 4.3.1 Social Stigma Associated with Sexually Transmitted Diseases Coupled with Rising Product Recalls
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug
    • 5.1.1 Acyclovir
    • 5.1.2 Valacyclovir
    • 5.1.3 Famciclovir
    • 5.1.4 Others
  • 5.2 By Route of Administration
    • 5.2.1 Oral
    • 5.2.2 Injection
    • 5.2.3 Topical
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of The World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Teva Pharmaceuticals Inc.
    • 6.1.2 Apotex Inc.
    • 6.1.3 Mylan Pharmaceuticals Inc.
    • 6.1.4 Epi Health LLC
    • 6.1.5 Zydus Pharmaceuticals
    • 6.1.6 GlaxoSmithKline LLC
    • 6.1.7 Carlsbad Tech
    • 6.1.8 Avet Pharmaceuticals Inc.
    • 6.1.9 Glenmark Pharmaceuticals
    • 6.1.10 Fresenius Kabi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q